Commercial Roche to lay off 300 to 400 employees in...

Roche to lay off 300 to 400 employees in product development jobs

-

Roche’s executives, including CMO (Chief Medical Officer) Levi Garraway, claimed in a recorded video conference with staff acquired by Swiss Newspaper Blick, that the company is planning to slash 300 to 400 jobs at PD (Product Development) locations, this year.

Roche has a global workforce of 101,000 employees. The Basel-based corporation has acknowledged the video conversation and stated that the company will cooperate with all the staff members and assist them to cope with the loss of their jobs.

The company operates product development locations in Switzerland, United Kingdom, China, United States, and Canada, and other locations, where personnel’s responsibilities include clinical investigations for potential pharmaceuticals developed under many research programs.

Project delivery, project management, coaching, learning and development, administrative support, and business management are among the jobs that are affected as a result of employees cut down, stated by Roche’s manager in a video conference.

From August through October, workers who are about to lose their jobs will be notified, with British employees being notified first then the workers in other locations. In the Video, an HR (Human Resources) manager claimed that their duties will end in early November.

“This is the hardest thing I’ve had to do since I’ve been in Roche,” Head of global drug safety, Felix Arellano, said on the recording.
In 2020, Roche reported a net profit of $16.3 billion (15.1 billion Swiss francs), boosted by pandemic diagnostics that helped to overcome the declining medicine sales

Latest news

Health-Tech Startup Evidation Opens Up Its Symptom-Logging App To Track Migraine Discomfort

California health technology firm Evidation is making its app for logging symptoms more open to track how migraine symptoms....

According to research, Gilead’s long-acting HIV medication is superior to Truvada

Gilead Sciences (GILD.O) announced that in a late-stage trial, its injectable treatment, lenacapavir, was 40.2% more effective in preventing...

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you